Tags: Pfizer Lung Cancer Drug to Get Speedy U.S. Review

Pfizer Lung Cancer Drug to Get Speedy US Review

Tuesday, 17 May 2011 11:42 AM EDT

Pfizer Inc's experimental lung cancer drug will be reviewed on a priority basis by U.S. health regulators, the drugmaker said on Tuesday.

The drug, crizotinib, is one of the most important drugs in the late-stage pipeline for Pfizer, the world's largest drugmaker which is increasingly pushing into oncology. Pfizer is seeking approval for crizotinib for the treatment of patients with a certain form of advanced non-small cell lung cancer.

By granting priority review, the Food and Drug Administration will accelerate the review time to a goal of six months as opposed to the usual 10 to 12 months. Such reviews are given to products considered to be potentially significant therapeutic advancements over existing therapies.

Pfizer also said it filed its crizotinib application with Japanese regulators.

© 2024 Thomson/Reuters. All rights reserved.


Markets
Pfizer Inc'sexperimental lung cancer drug will be reviewed on a priority basis by U.S. health regulators, the drugmaker said on Tuesday.The drug, crizotinib, is one of the most important drugs in the late-stage pipeline for Pfizer, the world's largest drugmaker which is...
Pfizer Lung Cancer Drug to Get Speedy U.S. Review
125
2011-42-17
Tuesday, 17 May 2011 11:42 AM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Get Newsmax Text Alerts
TOP

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved